Quotient Therapeutics, a startup that studies how genetic variations cause some cells to become diseased while others remain healthy, has formed a partnership with pharmaceutical giant Merck. The collaboration aims to identify new drug targets for inflammatory bowel disease (IBD) through genetic research.
Quotient Therapeutics is backed by Flagship Pioneering, the venture capital firm known for founding companies like Moderna. The startup focuses on understanding how small genetic differences can determine cellular health outcomes, a field that could unlock new therapeutic approaches for various diseases.